High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center

Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M et al (2021) Cancer and COVID-19: analysis of patient outcomes. Future Oncol 17(26):3499–3510. https://doi.org/10.2217/fon-2021-0121

Article  CAS  Google Scholar 

Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K et al (2021) Clinical characteristics and predictors of 28-day mortality in 352 critically Ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health 11(1):98–104. https://doi.org/10.2991/jegh.k.200928.001

Article  Google Scholar 

Alwani M, Yassin A, Al-Zoubi RM, Aboumarzouk OM, Nettleship J, Kelly D et al (2021) Sex-based differences in severity and mortality in COVID-19. Rev Med Virol 31(6):e2223. https://doi.org/10.1002/rmv.2223

Article  CAS  Google Scholar 

Atas N, Eroglu GA, Sodan HN, Ozturk BO, Babaoglu H, Satis H et al (2021) Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol 39(5):30–36. https://doi.org/10.55563/clinexprheumatol/815tdt

Article  Google Scholar 

Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H et al (2021) Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis 103:288–296. https://doi.org/10.1016/j.ijid.2020.11.149

Article  CAS  Google Scholar 

Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM et al (2020) The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 67(11):e28581. https://doi.org/10.1002/pbc.28581

Article  CAS  Google Scholar 

Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, Barbetta L et al (2021) Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. J Allergy Clin Immunol 147(2):561-566.e564. https://doi.org/10.1016/j.jaci.2020.11.006

Article  CAS  Google Scholar 

Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D et al (2020) Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2(6):e325–e331. https://doi.org/10.1016/s2665-9913(20)30127-2

Article  Google Scholar 

Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G et al (2021) Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol 3(4):e253–e261. https://doi.org/10.1016/s2665-9913(21)00012-6

Article  Google Scholar 

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (2022) National Institutes of Health. Retrieved from https://www.covid19treatmentguidelines.nih.gov/. Accessed 8 Aug 2022

Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720–3732. https://doi.org/10.1182/blood-2010-07-273417

Article  CAS  Google Scholar 

Fan X, Nowell DL (2011) Using propensity score matching in educational research. Gift Child Q 55(1):74–79. https://doi.org/10.1177/0016986210390635

Article  Google Scholar 

Feld J, Tremblay D, Thibaud S, Kessler A, Naymagon L (2020) Ferritin levels in patients with COVID-19: a poor predictor of mortality and hemophagocytic lymphohistiocytosis. Int J Lab Hematol 42(6):773–779. https://doi.org/10.1111/ijlh.13309

Article  Google Scholar 

Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6(4):232–241. https://doi.org/10.1038/nrrheum.2010.4

Article  CAS  Google Scholar 

Gavand PE, Serio I, Arnaud L, Costedoat-Chalumeau N, Carvelli J, Dossier A et al (2017) Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients. Autoimmun Rev 16(7):743–749. https://doi.org/10.1016/j.autrev.2017.05.010

Article  CAS  Google Scholar 

Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24(6):731–738. https://doi.org/10.1038/s41591-018-0041-7

Article  CAS  Google Scholar 

Gilboa M, Bornstein G, Ben-Zvi I, Grossman C (2020) Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review. Rheumatol Int 40(4):663–669. https://doi.org/10.1007/s00296-019-04393-7

Article  Google Scholar 

Grom AA, Horne A, De Benedetti F (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12(5):259–268. https://doi.org/10.1038/nrrheum.2015.179

Article  CAS  Google Scholar 

Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA (2020) Thrombosis in COVID-19. Am J Hematol 95(12):1578–1589. https://doi.org/10.1002/ajh.25982

Article  CAS  Google Scholar 

Hong D, Yang Z, Han S, Liang X, Ma K, Zhang X (2014) Interleukin 1 inhibition with anakinra in adult-onset still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther 8:2345–2357. https://doi.org/10.2147/dddt.S73428

Article  Google Scholar 

Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93(1):250–256. https://doi.org/10.1002/jmv.26232

Article  CAS  Google Scholar 

Karakike E, Dalekos GN, Koutsodimitropoulos I, Saridaki M, Pourzitaki C, Papathanakos G et al (2022) ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients. J Innate Immun 14(3):218–228. https://doi.org/10.1159/000519090

Article  CAS  Google Scholar 

Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P et al (2021) Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol 3(10):e690–e697. https://doi.org/10.1016/s2665-9913(21)00216-2

Article  Google Scholar 

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924

Article  CAS  Google Scholar 

López-Reyes A, Martinez-Armenta C, Espinosa-Velázquez R, Vázquez-Cárdenas P, Cruz-Ramos M, Palacios-Gonzalez B et al (2020) NLRP3 inflammasome: the stormy link between obesity and COVID-19. Front Immunol 11:570251. https://doi.org/10.3389/fimmu.2020.570251

Article  CAS  Google Scholar 

Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS (2020) Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol 2(6):e358–e367. https://doi.org/10.1016/s2665-9913(20)30096-5

Article  Google Scholar 

Ñamendys-Silva SA, Alvarado-Ávila PE, Domínguez-Cherit G, Rivero-Sigarroa E, Sánchez-Hurtado LA, Gutiérrez-Villaseñor A et al (2021) Outcomes of patients with COVID-19 in the intensive care unit in Mexico: a multicenter observational study. Heart Lung 50(1):28–32. https://doi.org/10.1016/j.hrtlng.2020.10.013

Article  Google Scholar 

Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545–555. https://doi.org/10.1002/art.30128

Article  CAS  Google Scholar 

Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S (2021) Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J 19(1):98. https://doi.org/10.1186/s12969-021-00585-3

Article  Google Scholar 

Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E et al (2021) A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol 73(8):1533–1542. https://doi.org/10.1002/art.41699

Article  CAS  Google Scholar 

Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H (2020) The novel coronavirus disease-2019 (COVID-19): mechanism of action, detection and recent therapeutic strategies. Virology 551:1–9. https://doi.org/10.1016/j.virol.2020.08.011

Article  CAS  Google Scholar 

Tang L, Yin Z, Hu Y, Mei H (2020) Controlling cytokine storm is vital in COVID-19. Front Immunol 11:570993. https://doi.org/10.3389/fimmu.2020.570993

Article  CAS  Google Scholar 

Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M et al (2020) Hematological findings and complications of COVID-19. Am J Hematol 95(7):834–847. https://doi.org/10.1002/ajh.25829

Article  CAS  Google Scholar 

Vora SM, Lieberman J, Wu H (2021) Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol 21(11):694–703. https://doi.org/10.1038/s41577-021-00588-x

Article  CAS  Google Scholar 

Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A et al (2020) Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol 2(12):e754–e763. https://doi.org/10.1016/S2665-9913(20)30343-X

Article  Google Scholar 

WHO (2020) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. WHO, Geneva

Google Scholar 

Zhao X, Li Y, Ge Y, Shi Y, Lv P, Zhang J et al (2021) Evaluation of nutrition risk and its association with mortality risk in severely and critically ill COVID-19 patients. JPEN J Parenter Enteral Nutr 45(1):32–42. https://doi.org/10.1002/jpen.1953

Article  CAS  Google Scholar 

Zou LX, Zhu Y, Sun L, Ma HH, Yang SR, Zeng HS et al (2020) Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China. World J Pediatr 16(1):89–98. https://doi.org/10.1007/s12519-019-00256-0

Article  CAS  Google Scholar 

留言 (0)

沒有登入
gif